Roche Receives CE Mark For Elecsys IGRA TB Blood Test, Expanding Global Access To Tuberculosis Infection Testing Toward WHO Elimination Targets
هوفمان-لا روش ADR
هوفمان-لا روش
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
- The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets.
- Performed on Roche’s industry-leading and widely available cobas immunoassay systems, the test enables laboratories to meet growing tuberculosis infection testing needs by reducing reliance on manual workflows through automation and digital solutions.
- The new solution provides rapid, high-throughput, and cost-effective tuberculosis testing, delivers reliable results in under 24 hours and cuts standard processing times in half to just 19 minutes per patient.